Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 1

Status

Active not recruiting 3Unknown 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 3Plasma cell 2

Conditions

Triple Negative Breast Neoplasms 3Smoldering Multiple Myeloma 2Breast Neoplasms 2Neoplasms, Plasma Cell 1

Interventions

Cyclophosphamide 3162Cisplatin 3160Carboplatin 2938Paclitaxel 2673Radiotherapy 2648Gemcitabine 2547pembrolizumab 2331Docetaxel 2157Bevacizumab 2128Fluorouracil 1822Capecitabine 1784Oxaliplatin 1713Dexamethasone 1590Nivolumab 1517Doxorubicin 1477Rituximab 1454Etoposide 1342Magnetic Resonance Spectroscopy 1266Irinotecan 1235Leucovorin 1216Cytarabine 1123Pemetrexed 1062Drug Therapy 1062fludarabine 1050Vincristine 956Specimen Handling 936Prednisone 926Cetuximab 921Lenalidomide 916Trastuzumab 902

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × PVX-410 vaccine × Clear all
NCT02886065 2026-03-13

A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

Massachusetts General Hospital

Phase 1 Active not recruiting
19 enrolled
Plasma cell

Smoldering Multiple Myeloma, Neoplasms, Plasma Cell

NCT02826434 2025-10-01

Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer

Massachusetts General Hospital

Phase 1 Active not recruiting
22 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03362060 2025-10-01

PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer

Massachusetts General Hospital

Phase 1 Active not recruiting
20 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04634747 2022-04-20

Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer

OncoPep, Inc.

Phase 2 Unknown
53 enrolled
Breast

Triple Negative Breast Neoplasms

NCT01718899 2016-09-28

Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma

OncoPep, Inc.

Phase 1 Completed
22 enrolled
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡